$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options
Novartis Aims To Provide Update ‘Towards End Of 2022’
Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.
